R Lieberman

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. ncbi request reprint Prostate cancer chemoprevention agent development: the National Cancer Institute, Division of Cancer Prevention portfolio
    Howard L Parnes
    Prostate and Urologic Cancer Researh Group, Division of Cancer Prevention, National Cancer Institute, National Institute of Health, Bethesda, Maryland, USA
    J Urol 171:S68-74; discussion S75. 2004
  2. ncbi request reprint Evidence-based medical perspectives: the evolving role of PSA for early detection, monitoring of treatment response, and as a surrogate end point of efficacy for interventions in men with different clinical risk states for the prevention and progression o
    Ronald Lieberman
    Division of Cancer Prevention, National Cancer Institute, Rockville, Maryland, USA
    Am J Ther 11:501-6. 2004
  3. ncbi request reprint Executive Summary of the National Cancer Institute Workshop: Highlights and recommendations
    R Lieberman
    National Cancer Institute, Rockville, Maryland, USA
    Urology 57:4-27. 2001
  4. ncbi request reprint Evolving strategies for prostate cancer chemoprevention trials
    Ronald Lieberman
    Division of Cancer Prevention, National Cancer Institute, 6130 Executive Blvd Room EPN 2102, Rockville MD 20852, USA
    World J Urol 21:3-8. 2003
  5. ncbi request reprint Prostate cancer chemoprevention: Strategies for designing efficient clinical trials
    R Lieberman
    National Cancer Institute, Rockville, Maryland 20852, USA
    Urology 57:224-9. 2001
  6. ncbi request reprint Chemoprevention of prostate cancer: current status and future directions
    Ronald Lieberman
    Prostate and Urologic Cancer Research Group, Division of Cancer Prevention, National Cancer Institute, Rockville, MD 20852, USA
    Cancer Metastasis Rev 21:297-309. 2002
  7. ncbi request reprint Development of new cancer chemoprevention agents: role of pharmacokinetic/pharmacodynamic and intermediate endpoint biomarker monitoring
    R Lieberman
    Chemoprevention Branch, National Cancer Institute, Rockville, MD 20852, USA
    Clin Chem 44:420-7. 1998
  8. ncbi request reprint Progress in cancer chemoprevention
    G J Kelloff
    National Cancer Institute, Division of Cancer Prevention, Bethesda, Maryland 20892, USA
    Ann N Y Acad Sci 889:1-13. 1999
  9. ncbi request reprint Chemoprevention of superficial bladder cancer
    R Lieberman
    Prostate and Urologic Cancer Research Group, Division of Cancer Prevention, National Cancer Institute, 6130 Executive Boulevard, EPN 201, Rockville, MD 20852, USA
    Cancer Treat Res 106:237-54. 2001
  10. ncbi request reprint Agents, biomarkers, and cohorts for chemopreventive agent development in prostate cancer
    G J Kelloff
    National Cancer Institute, Division of Cancer Prevention, Bethesda, Maryland, USA
    Urology 57:46-51. 2001

Collaborators

Detail Information

Publications23

  1. ncbi request reprint Prostate cancer chemoprevention agent development: the National Cancer Institute, Division of Cancer Prevention portfolio
    Howard L Parnes
    Prostate and Urologic Cancer Researh Group, Division of Cancer Prevention, National Cancer Institute, National Institute of Health, Bethesda, Maryland, USA
    J Urol 171:S68-74; discussion S75. 2004
    ..We describe the current National Cancer Institute chemoprevention agent development program and provide a summary of the intermediate end points used...
  2. ncbi request reprint Evidence-based medical perspectives: the evolving role of PSA for early detection, monitoring of treatment response, and as a surrogate end point of efficacy for interventions in men with different clinical risk states for the prevention and progression o
    Ronald Lieberman
    Division of Cancer Prevention, National Cancer Institute, Rockville, Maryland, USA
    Am J Ther 11:501-6. 2004
    ....
  3. ncbi request reprint Executive Summary of the National Cancer Institute Workshop: Highlights and recommendations
    R Lieberman
    National Cancer Institute, Rockville, Maryland, USA
    Urology 57:4-27. 2001
    ..Finally, each expert panel generated recommendations for areas of future research emphasizing opportunities and infrastructure needs...
  4. ncbi request reprint Evolving strategies for prostate cancer chemoprevention trials
    Ronald Lieberman
    Division of Cancer Prevention, National Cancer Institute, 6130 Executive Blvd Room EPN 2102, Rockville MD 20852, USA
    World J Urol 21:3-8. 2003
    ..In summary, a dual strategy for CP is being developed which includes public health measures and a medical intervention approach...
  5. ncbi request reprint Prostate cancer chemoprevention: Strategies for designing efficient clinical trials
    R Lieberman
    National Cancer Institute, Rockville, Maryland 20852, USA
    Urology 57:224-9. 2001
    ....
  6. ncbi request reprint Chemoprevention of prostate cancer: current status and future directions
    Ronald Lieberman
    Prostate and Urologic Cancer Research Group, Division of Cancer Prevention, National Cancer Institute, Rockville, MD 20852, USA
    Cancer Metastasis Rev 21:297-309. 2002
    ....
  7. ncbi request reprint Development of new cancer chemoprevention agents: role of pharmacokinetic/pharmacodynamic and intermediate endpoint biomarker monitoring
    R Lieberman
    Chemoprevention Branch, National Cancer Institute, Rockville, MD 20852, USA
    Clin Chem 44:420-7. 1998
    ..g., laser capture microdissection and cDNA chip microarrays that assess gene expression patterns of precancerous and cancerous lesions...
  8. ncbi request reprint Progress in cancer chemoprevention
    G J Kelloff
    National Cancer Institute, Division of Cancer Prevention, Bethesda, Maryland 20892, USA
    Ann N Y Acad Sci 889:1-13. 1999
    ..g., local delivery to cancer targets, agent combinations, and pharmacodynamically guided dosing)...
  9. ncbi request reprint Chemoprevention of superficial bladder cancer
    R Lieberman
    Prostate and Urologic Cancer Research Group, Division of Cancer Prevention, National Cancer Institute, 6130 Executive Boulevard, EPN 201, Rockville, MD 20852, USA
    Cancer Treat Res 106:237-54. 2001
    ....
  10. ncbi request reprint Agents, biomarkers, and cohorts for chemopreventive agent development in prostate cancer
    G J Kelloff
    National Cancer Institute, Division of Cancer Prevention, Bethesda, Maryland, USA
    Urology 57:46-51. 2001
    ..Cohort selection should be based on various patient characteristics (stage of the disease, previous cancers or premalignant lesions, or high risk factors) and should be conducted within the context of standard treatment...
  11. ncbi request reprint Computer-assisted image analysis-derived intermediate endpoints
    C W Boone
    National Cancer Institute, Bethesda, Maryland, USA
    Urology 57:129-31. 2001
    ....
  12. ncbi request reprint Pharmacodynamics and pharmacokinetics of a 72-hour infusion of 9-aminocamptothecin in adult cancer patients
    C H Takimoto
    National Cancer Institute Navy Medical Oncology Branch, Division of Clinical Sciences, National Cancer Institute, National Naval Medical Center, Bethesda, MD 20889 5105, USA
    J Clin Oncol 15:1492-501. 1997
    ..To investigate the pharmacokinetics and pharmacodynamics of 9-aminocamptothecin (9-AC) infused over 72 hours at doses of 5 to 74 micrograms/m2/h...
  13. ncbi request reprint Androgen deprivation therapy for prostate cancer chemoprevention: current status and future directions for agent development
    R Lieberman
    Prostate and Urologic Cancer Research Group, Division of Cancer Prevention, National Cancer Institute, Rockville, Maryland 20852, USA
    Urology 58:83-90. 2001
    ..Several agent classes have a strong basis for combination with ADT, including antiproliferatives, antioxidant micronutrients (selenium), antiestrogens, and nonsteroidal anti-inflammatory drugs (selective cyclooxygenase-2 inhibitors)...
  14. ncbi request reprint Design and progress of a trial of selenium to prevent prostate cancer among men with high-grade prostatic intraepithelial neoplasia
    James R Marshall
    Roswell Park Cancer Institute, Buffalo, NY 14263, USA
    Cancer Epidemiol Biomarkers Prev 15:1479-84. 2006
    ..Subject accrual is expected to be completed by the fall of 2006, with trial completion in 2009...
  15. pmc The effect of difluoromethylornithine on decreasing prostate size and polyamines in men: results of a year-long phase IIb randomized placebo-controlled chemoprevention trial
    Anne R Simoneau
    Department of Medicine, University of California, Irvine, 101 The City Drive, Route 81, Building 55, Room 304, Orange, CA 92868, USA
    Cancer Epidemiol Biomarkers Prev 17:292-9. 2008
    ..The prostate has high levels of tissue polyamines and has shown sensitivity to DFMO both in vitro and in vivo...
  16. doi request reprint Lycopene in cancer prevention and treatment
    Soley Seren
    Department of Internal Medicine, Wayne State University, Barbara Ann Karmanos Cancer Institute, Detroit, Michigan 48201, USA
    Am J Ther 15:66-81. 2008
    ..Further mechanistic studies and randomized controlled clinical intervention trials with lycopene involving cancer patients are warranted...
  17. ncbi request reprint Effect of an epidermal growth factor receptor tyrosine kinase inhibitor on actin remodeling in an in vitro bladder cancer carcinogenesis model
    YuSheng Jin
    Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California at Los Angeles, Box 951732, Los Angeles, CA 90095 1732, USA
    Mol Cancer Ther 5:1754-63. 2006
    ..The findings provide evidence to support erlotinib-based bladder cancer chemoprevention and using actin remodeling as a marker for erlotinib-based intervention trials...
  18. ncbi request reprint Flutamide in men with prostatic intraepithelial neoplasia: a randomized, placebo-controlled chemoprevention trial
    Steven R Alberts
    Mayo Clinic and Mayo Foundation, Rochester, Minnesota, USA
    Am J Ther 13:291-7. 2006
    ..Quality-of-life measures did not show any differences between the 2 groups. This study showed no evidence of benefit from flutamide as a chemoprevention agent in men with HGPIN...
  19. ncbi request reprint Changes in serum proteomic patterns by presurgical alpha-tocopherol and L-selenomethionine supplementation in prostate cancer
    Jeri Kim
    Department of Genitourinary Medical Oncology, University of Massachusetts Medical School, Lazare Research Building, Room 504, 364 Plantation Street, Worcester, MA 01605 2324, USA
    Cancer Epidemiol Biomarkers Prev 14:1697-702. 2005
    ..To determine the effects of selenium and vitamin E in blood and prostate tissue, we undertook a preoperative feasibility study complementary to the currently ongoing Selenium and Vitamin E Cancer Prevention Trial...
  20. ncbi request reprint Antiandrogen, vaccine and combination therapy in patients with nonmetastatic hormone refractory prostate cancer
    Philip M Arlen
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Urol 174:539-46. 2005
    ..This trial was designed to analyze toxicity, immunogenicity and time to treatment failure using vaccine, antiandrogen therapy or their sequential use...
  21. ncbi request reprint Prolonged response to nilutamide in a patient with stage D0.5 prostate cancer who previously failed androgen deprivation therapy
    Nushin F Todd
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA
    Am J Ther 12:172-4. 2005
    ..Further investigation of the potential role of nilutamide therapy as second-line antiandrogen therapy is warranted as monotherapy and/or in combination with other promising novel approaches including PSA-based vaccines...
  22. ncbi request reprint A pilot surrogate end point biomarker trial of perillyl alcohol in breast neoplasia
    Vered Stearns
    Breast Cancer Program, Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, D C, USA
    Clin Cancer Res 10:7583-91. 2004
    ..We report our experience with the natural compound perillyl alcohol (POH) administered in a short-term surrogate end point biomarker (SEB) protocol, using the "window" between diagnostic and definitive surgery...
  23. ncbi request reprint Clinical trials referral resource. Current NCI-sponsored clinical trials in prostate cancer: prevention, treatment, supportive care, and imaging
    Alison Martin
    National Cancer Institute, Division of Cancer Treatment and Diagnosis, Bethesda, MD, USA
    Oncology (Williston Park) 17:1097-8, 1103-5, 1110-6. 2003